相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。North American Study for the Treatment of Recurrent Epistaxis with Doxycycline: The NOSTRIL trial
Justin P. McWilliams et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)
Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia
Joseph G. Parambil et al.
ANGIOGENESIS (2022)
An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study
Hanny Al-Samkari et al.
HAEMATOLOGICA (2021)
Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care
Hanny Al-Samkari
BLOOD (2021)
Selumetinib: the first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma
Sabyasachi Mukhopadhyay et al.
CURRENT MEDICAL RESEARCH AND OPINION (2021)
An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia
Hanny Al-Samkari et al.
HAEMOPHILIA (2020)
Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia
Marie E. Faughnan et al.
ANNALS OF INTERNAL MEDICINE (2020)
Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia–Related Bleeding and High-Output Cardiac Failure
Hasan Ahmad Hasan Albitar et al.
MAYO CLINIC PROCEEDINGS (2020)
A hematologic support score for longitudinal measurement of blood and iron requirements in hereditary hemorrhagic telangiectasia and other chronic bleeding disorders
Hanny Al-Samkari et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)
Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia
Marie E. Faughnan et al.
ANGIOGENESIS (2019)
Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia
H. Al-Samkari et al.
JOURNAL OF INTERNAL MEDICINE (2019)
Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia
Elisabetta Buscarini et al.
ORPHANET JOURNAL OF RARE DISEASES (2019)
Systemic Bevacizumab for Hereditary Hemorrhagic Telangiectasia: Considerations from Observational Studies
Hanny Al-Samkari
OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2019)
Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life
Mehmet Baysal et al.
TURKISH JOURNAL OF HEMATOLOGY (2019)
Vascular Anomalies Diagnosis of Complicated Anomalies and New Medical Treatment Options
Denise M. Adams et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2019)
Intramuscular fast-flow vascular anomaly contains somatic MAP2K1 and KRAS mutations
Jeremy A. Goss et al.
ANGIOGENESIS (2019)
Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers
Hanny Al-Samkari et al.
ORPHANET JOURNAL OF RARE DISEASES (2019)
High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations
Tao Hong et al.
BRAIN (2019)
Somatic mutations in intracranial arteriovenous malformations
Jeremy A. Goss et al.
PLOS ONE (2019)
Genotype-Guided Medical Treatment of an Arteriovenous Malformation in a Child
Ramrada Lekwuttikarn et al.
JAMA DERMATOLOGY (2019)
Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective
Athena Kritharis et al.
HAEMATOLOGICA (2018)
Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy
Lara Al-Olabi et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Phosphatidylinositol 3-Kinase -Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
Dejan Juric et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding
Vivek N. Iyer et al.
MAYO CLINIC PROCEEDINGS (2018)
Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain
S. I. Nikolaev et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pneumocystis Jirovecii Pneumonia During Sirolimus Therapy for Kaposiform Hemangioendothelioma
Thomas B. Russell et al.
PEDIATRICS (2018)
Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective
Athena Kritharis et al.
HAEMATOLOGICA (2018)
Targeted therapy in patients with PIK3CA-related overgrowth syndrome
Quitterie Venot et al.
NATURE (2018)
Longterm Data on Sirolimus Treatment in Patients with Lupus Nephritis
Desmond Y. H. Yap et al.
JOURNAL OF RHEUMATOLOGY (2018)
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
Alex A. Adjei et al.
INVESTIGATIONAL NEW DRUGS (2017)
Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study
Jia Fang et al.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2017)
Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies
Tomoyuki Mizuno et al.
PEDIATRIC BLOOD & CANCER (2017)
Depression and post-traumatic stress disorder in individuals with hereditary hemorrhagic telangiectasia: A cross-sectional survey
Shruti Chaturvedi et al.
THROMBOSIS RESEARCH (2017)
Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients
Alexandre Guilhem et al.
PLOS ONE (2017)
Somatic MAP2K1 Mutations Are Associated with Extracranial Arteriovenous Malformation
Javier A. Couto et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2017)
The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia
Linda X. Yin et al.
LARYNGOSCOPE (2016)
GNA14 Somatic Mutation Causes Congenital and Sporadic Vascular Tumors by MAPK Activation
Young H. Lim et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2016)
Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies
Denise M. Adams et al.
PEDIATRICS (2016)
Immunization practices in solid organ transplant recipients
Isao Miyairi et al.
VACCINE (2016)
Pomalidomide in Hereditary Hemorrhagic Telangiectasia: Interim Results of a Phase I Study
Mohamed Samour et al.
BLOOD (2016)
Thalidomide Effects in Patients with Hereditary Hemorrhagic Telangiectasia During Therapeutic Treatment and in Fli-EGFP Transgenic Zebrafish Model
Hong-Ling Peng et al.
CHINESE MEDICAL JOURNAL (2015)
Treatment of complex periorbital venolymphatic malformation in a neonate with a combination therapy of sirolimus and prednisolone
David Kim et al.
DERMATOLOGIC THERAPY (2015)
Sirolimus for the Treatment of a Massive Capillary-Lymphatico-Venous Malformation: A Case Report
Aleksandar M. Vlahovic et al.
PEDIATRICS (2015)
Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study
Rosangela Invernizzi et al.
LANCET HAEMATOLOGY (2015)
Treatment of a Tongue Lymphangioma With Sirolimus after Failure of Surgical Resection and Propranolol
Canan Akyuz et al.
PEDIATRIC BLOOD & CANCER (2014)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Sirolimus for the Treatment of Complicated Vascular Anomalies in Children
Adrienne M. Hammill et al.
PEDIATRIC BLOOD & CANCER (2011)
PI3K/AKT/mTOR pathway in angiogenesis
Jayashree Karar et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2011)
An Epistaxis Severity Score for Hereditary Hemorrhagic Telangiectasia
Jeffrey B. Hoag et al.
LARYNGOSCOPE (2010)
Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia
Franck Lebrin et al.
NATURE MEDICINE (2010)
Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis
S. Huber et al.
KIDNEY INTERNATIONAL (2007)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov et al.
MOLECULAR CELL (2006)
Growing roles for the mTOR pathway
DD Sarbassov et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
Developmental pharmacology - Drug disposition, action, and therapy in infants and children
GL Kearns et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
